A reanalysis of pain crises data from the pivotal L-glutamine in sickle cell disease trial

Ahmar U. Zaidi*, Jeremie Estepp, Nirmish Shah, Salam Alkindi, Hatoon Ezzat, Hung Lam, Caterina P. Minniti

*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلةمراجعة النظراء

3 اقتباسات (Scopus)

ملخص

The pivotal Endari trial in sickle cell disease showed a reduction in pain crises events. This reanalysis of the L-glutamine phase 3 trial using annual rates of pain crises, consistent with other SCD studies, supported the statistically significant outcomes of the original analysis. The observed 45% difference in the VOC rate is comparable to what was reported in other sickle cell therapeutics used to reduce the incidence of pain. The results presented in this communication are informative for clinicians evaluating treatment effects across available SCD therapeutic options based on studies that utilized VOC as the primary endpoint.

اللغة الأصليةEnglish
رقم المقال106546
دوريةContemporary Clinical Trials
مستوى الصوت110
المعرِّفات الرقمية للأشياء
حالة النشرPublished - نوفمبر 2021

ASJC Scopus subject areas

  • ???subjectarea.asjc.2700.2736???

بصمة

أدرس بدقة موضوعات البحث “A reanalysis of pain crises data from the pivotal L-glutamine in sickle cell disease trial'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا